Skip to content

Study · Randomized controlled trial · n = 61 · 2005

5 results

Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration.

Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN, Yang YS

Fertility and sterility1 Jun 2005Cited by 28 (Europe PMC)

PMID15950639 (opens in a new tab)DOI10.1016/j.fertnstert.2004.12.037 (opens in a new tab)PepBankPUB-15950639
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In COS patients, pregnancy rates did not differ significantly across single-dose cetrorelix, multiple-dose cetrorelix and long buserelin groups.

    In plain wordsIn COS patients, pregnancy rates did not differ significantly across single-dose cetrorelix, multiple-dose cetrorelix and long buserelin groups.

    Peptide
    Cetrorelix
    Outcome
    No significant changePregnancy rate
    Study

    n = 61

    Comparator
    Multiple-dose cetrorelix and long buserelin protocols
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The pregnancy and implantation rates did not differ significantly for the three study groups.
    3 context sentences
    Summary · context
    Randomized clinical trial.
    Summary · context
    Sixty-one patients undergoing controlled ovarian stimulation (COS) and IVF/ICSI.
    Summary · context
    COS with either a multiple-dose (MD) or a single-dose (SD) protocol for GnRH antagonist (cetrorelix) administration, or with a long protocol (LP) for GnRH agonist (buserelin) administration, followed by oocyte retrieval, IVF/ICSI, and embryo transfer.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In COS patients, implantation rates did not differ significantly across single-dose cetrorelix, multiple-dose cetrorelix and long buserelin groups.

    In plain wordsIn COS patients, implantation rates did not differ significantly across single-dose cetrorelix, multiple-dose cetrorelix and long buserelin groups.

    Peptide
    Cetrorelix
    Outcome
    No significant changeImplantation rate
    Study

    n = 61

    Comparator
    Multiple-dose cetrorelix and long buserelin protocols
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The pregnancy and implantation rates did not differ significantly for the three study groups.
    3 context sentences
    Summary · context
    Randomized clinical trial.
    Summary · context
    Sixty-one patients undergoing controlled ovarian stimulation (COS) and IVF/ICSI.
    Summary · context
    COS with either a multiple-dose (MD) or a single-dose (SD) protocol for GnRH antagonist (cetrorelix) administration, or with a long protocol (LP) for GnRH agonist (buserelin) administration, followed by oocyte retrieval, IVF/ICSI, and embryo transfer.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In COS patients, the single-dose cetrorelix protocol reduced follicular development compared with the long buserelin protocol.

    In plain wordsIn COS patients, follicular development was lower with single-dose cetrorelix than the long buserelin protocol.

    Peptide
    Cetrorelix
    Outcome
    DecreaseFollicular development
    Study

    n: not reported in source

    Comparator
    Long buserelin protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The SD protocol for cetrorelix was associated with a more reduced level of follicular development, lower levels of serum estradiol on the day of HCG administration, and a more reduced number of zygotes than the LP for buserelin.
    3 context sentences
    Summary · context
    Randomized clinical trial.
    Summary · context
    Sixty-one patients undergoing controlled ovarian stimulation (COS) and IVF/ICSI.
    Summary · context
    COS with either a multiple-dose (MD) or a single-dose (SD) protocol for GnRH antagonist (cetrorelix) administration, or with a long protocol (LP) for GnRH agonist (buserelin) administration, followed by oocyte retrieval, IVF/ICSI, and embryo transfer.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In COS patients, the single-dose cetrorelix protocol lowered estradiol on hCG day compared with the long buserelin protocol.

    In plain wordsIn COS patients, estradiol on hCG day was lower with single-dose cetrorelix than the long buserelin protocol.

    Peptide
    Cetrorelix
    Outcome
    DecreaseEstradiol on hCG day
    Study

    n: not reported in source

    Comparator
    Long buserelin protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The SD protocol for cetrorelix was associated with a more reduced level of follicular development, lower levels of serum estradiol on the day of HCG administration, and a more reduced number of zygotes than the LP for buserelin.
    3 context sentences
    Summary · context
    Randomized clinical trial.
    Summary · context
    Sixty-one patients undergoing controlled ovarian stimulation (COS) and IVF/ICSI.
    Summary · context
    COS with either a multiple-dose (MD) or a single-dose (SD) protocol for GnRH antagonist (cetrorelix) administration, or with a long protocol (LP) for GnRH agonist (buserelin) administration, followed by oocyte retrieval, IVF/ICSI, and embryo transfer.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In COS patients, the single-dose cetrorelix protocol reduced zygote numbers compared with the long buserelin protocol.

    In plain wordsIn COS patients, single-dose cetrorelix produced fewer zygotes than the long buserelin protocol.

    Peptide
    Cetrorelix
    Outcome
    DecreaseZygote number
    Study

    n: not reported in source

    Comparator
    Long buserelin protocol
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The SD protocol for cetrorelix was associated with a more reduced level of follicular development, lower levels of serum estradiol on the day of HCG administration, and a more reduced number of zygotes than the LP for buserelin.
    3 context sentences
    Summary · context
    Randomized clinical trial.
    Summary · context
    Sixty-one patients undergoing controlled ovarian stimulation (COS) and IVF/ICSI.
    Summary · context
    COS with either a multiple-dose (MD) or a single-dose (SD) protocol for GnRH antagonist (cetrorelix) administration, or with a long protocol (LP) for GnRH agonist (buserelin) administration, followed by oocyte retrieval, IVF/ICSI, and embryo transfer.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.